Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-10-13 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
第二届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 16th meeting of the 2nd Board of Directors of Enwei Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and the approval of a restricted stock incentive plan. The document is an official disclosure of board decisions rather than a full report or financial statement. It does not contain financial data or detailed management discussion but focuses on board meeting resolutions and related disclosures. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. No officer certification or regulatory filing is the primary content, so RNS is not appropriate.
2023-10-13 Chinese
关于向2023年限制性股票激励计划激励对象授予限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the granting of restricted stock under a 2023 restricted stock incentive plan by the company 恩威医药股份有限公司. It includes specifics such as the grant date, number of shares, grant price, eligibility criteria, approval procedures, performance conditions, and legal and financial advisor opinions. The content focuses on the equity incentive plan and the granting of shares to management and key employees. This type of document is a formal announcement of a share-based compensation plan and the granting of shares, which falls under capital structure changes related to share issuance or equity incentives. It is not a full financial report, audit report, or management discussion, nor is it a regulatory filing or announcement of a report publication. It is also not a director dealing or share repurchase. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a substantive disclosure about share issuance under an incentive plan.
2023-10-13 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 first extraordinary general meeting (临时股东大会) of Enwei Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the voting results and decisions made by shareholders during the meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full report like an annual or interim report, nor is it a simple notice or invitation. It is a formal announcement of voting outcomes from a shareholders meeting, fitting the DVA category with high confidence.
2023-10-13 Chinese
第二届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Enwei Pharmaceutical Co., Ltd. regarding the approval of a restricted stock incentive plan for 2023. It details the meeting date, attendance, legal compliance, and voting results on the stock incentive grant. There is no financial data, no full report, no earnings or audit information, and no mention of a shareholder meeting or voting results from a general meeting. The document is an official announcement of a board/management decision related to stock incentives, which fits best under Board/Management Information (MANG). The document length is short (1121 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-10-13 Chinese
北京金杜（成都）律师事务所关于恩威医药股份有限公司2023年第一次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and results of a company's 2023 first extraordinary general meeting (临时股东大会). It details the legal compliance of the meeting's call, attendance, voting procedures, and results. The document includes voting results on specific proposals and confirms the legality and validity of the meeting and its resolutions. It is not a financial report, earnings release, or management discussion, but rather a legal opinion related to a shareholder meeting. This type of document is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and related shareholder meeting information.
2023-10-13 Chinese
监事会关于2023 年限制性股票激励计划激励对象名单（授予日）的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion on the list of incentive recipients for a 2023 restricted stock incentive plan. It references relevant laws and regulations, confirms the eligibility of the incentive recipients, and is signed by supervisors. The document is short (1088 characters) and does not contain financial statements or detailed financial data. It is a formal opinion or verification related to a stock incentive plan rather than a full report or announcement of voting results. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is not a proxy solicitation or voting results announcement. It is a regulatory compliance-related document verifying the incentive plan participants. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2023-10-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.